Skip to main content
Clinical Trials/NCT02967146
NCT02967146UnknownPhase 3

Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer A Multicenter Double-blinded, Randomized Study

Samsung Medical Center2 sites in 2 countries170 target enrollmentStarted: November 2016Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Enrollment
170
Locations
2
Primary Endpoint
sum of ROM(range of motion)

Study Overview

Brief Summary

Anti-adhesive effect and Safety of a mixed solid of poloxamer, gelatin and chitosan(Mediclore®) after axillary dissection for breast cancer

Detailed Description

A Multicenter Double-blinded, Randomized Study

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • the patients needed axillary dissection in breast cancer
  • Written informed consent
  • Patients without clinically significant lab
  • the patients who are diagnosed 'positive for metastasis' by sentinel lymph node biopsy

Exclusion Criteria

  • having enrolled another clinical trials within 1 month
  • Immunosuppression or autoimmune disease
  • Anticoagulant, general steroids within a week from surgery
  • Incompatible medications
  • Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies)

Outcomes

Primary Outcomes

sum of ROM(range of motion)

Time Frame: 4weeks

to compare the differences of sum of ROM between two groups comparision of the differences of sum of ROM between two groups ROM: forward flexion and horizontal abduction

Secondary Outcomes

  • pain assessment (numeric pain rating scale)(4weeks, 24weeks)
  • sum of ROM(range of motion)(24weeks)
  • Scoring DASH(Disablities of the arm, shoulder and hand)(4weeks, 24weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Seok Won Kim

MD

Samsung Medical Center

Study Sites (2)

Loading locations...

Similar Trials